Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Acute toxicity and patient‐reported outcomes in anal canal cancer: results of a pilot study

Acute toxicity and patient‐reported outcomes in anal canal cancer: results of a pilot study IntroductionChemoradiotherapy (CRT) is well established as the gold standard treatment for squamous cell anal canal cancer (ACC).1–3 Although shown to be effective, it has been associated with considerable acute and late toxicity. In more recent times, highly conformal radiation therapy techniques, such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), have been developed to facilitate dose reduction to surrounding organs at risk (OAR) whilst still delivering high doses to the tumour volume.4–6 As such, these techniques are now recognised as best practice for radiation therapy treatment.6 CRT still results in considerable toxicity for the patient and can negatively impact their quality of life (QoL).7 These toxicities can include perineal skin soreness, abdominal pain, diarrhoea and faecal incontinence impacting a patient's ability to resume social activities without feelings of anxiety and distress.7There has been increasing focus in health care in recent times on gathering patient‐reported outcomes (PROs). The Food and Drug Administration defines PROs as a ‘measurement of any aspect of a patient's health status that comes directly from the patient (i.e. without the interpretation of the patient's responses by a physician or anyone else)’, including disease symptoms, patient functioning and QoL.8 PROs can provide important http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Medical Radiation Sciences Wiley

Acute toxicity and patient‐reported outcomes in anal canal cancer: results of a pilot study

Acute toxicity and patient‐reported outcomes in anal canal cancer: results of a pilot study

Journal of Medical Radiation Sciences , Volume 69 (4) – Dec 1, 2022

Abstract

IntroductionChemoradiotherapy (CRT) is well established as the gold standard treatment for squamous cell anal canal cancer (ACC).1–3 Although shown to be effective, it has been associated with considerable acute and late toxicity. In more recent times, highly conformal radiation therapy techniques, such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), have been developed to facilitate dose reduction to surrounding organs at risk (OAR) whilst still delivering high doses to the tumour volume.4–6 As such, these techniques are now recognised as best practice for radiation therapy treatment.6 CRT still results in considerable toxicity for the patient and can negatively impact their quality of life (QoL).7 These toxicities can include perineal skin soreness, abdominal pain, diarrhoea and faecal incontinence impacting a patient's ability to resume social activities without feelings of anxiety and distress.7There has been increasing focus in health care in recent times on gathering patient‐reported outcomes (PROs). The Food and Drug Administration defines PROs as a ‘measurement of any aspect of a patient's health status that comes directly from the patient (i.e. without the interpretation of the patient's responses by a physician or anyone else)’, including disease symptoms, patient functioning and QoL.8 PROs can provide important

Loading next page...
 
/lp/wiley/acute-toxicity-and-patient-reported-outcomes-in-anal-canal-cancer-scgxsKu0Rc

References (23)

Publisher
Wiley
Copyright
Copyright © 2022 Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology
ISSN
2051-3895
eISSN
2051-3909
DOI
10.1002/jmrs.604
Publisher site
See Article on Publisher Site

Abstract

IntroductionChemoradiotherapy (CRT) is well established as the gold standard treatment for squamous cell anal canal cancer (ACC).1–3 Although shown to be effective, it has been associated with considerable acute and late toxicity. In more recent times, highly conformal radiation therapy techniques, such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), have been developed to facilitate dose reduction to surrounding organs at risk (OAR) whilst still delivering high doses to the tumour volume.4–6 As such, these techniques are now recognised as best practice for radiation therapy treatment.6 CRT still results in considerable toxicity for the patient and can negatively impact their quality of life (QoL).7 These toxicities can include perineal skin soreness, abdominal pain, diarrhoea and faecal incontinence impacting a patient's ability to resume social activities without feelings of anxiety and distress.7There has been increasing focus in health care in recent times on gathering patient‐reported outcomes (PROs). The Food and Drug Administration defines PROs as a ‘measurement of any aspect of a patient's health status that comes directly from the patient (i.e. without the interpretation of the patient's responses by a physician or anyone else)’, including disease symptoms, patient functioning and QoL.8 PROs can provide important

Journal

Journal of Medical Radiation SciencesWiley

Published: Dec 1, 2022

Keywords: anal canal cancer; patient reported outcomes; toxicity; volumetric modulated arc therapy (VMAT)

There are no references for this article.